Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says

Stifel initiated coverage on Immunic Inc. (NASDAQ: IMUX), a late-stage biotech developing oral therapies for neurologic and gastrointestinal diseases. The article is a routine analyst-coverage update and does not include a rating, price target, or other material financial figures. Market impact is likely limited unless additional details on the initiation are released.

Analysis

Stifel initiated coverage on Immunic Inc. (NASDAQ: IMUX), a late-stage biotech developing oral therapies for neurologic and gastrointestinal diseases. The article is a routine analyst-coverage update and does not include a rating, price target, or other material financial figures. Market impact is likely limited unless additional details on the initiation are released.